Zhi-Nan Chen, academician of Chinese Academy of Engineering; Expert in tumorous cytobiology and biopharmaceutics. Director of National Translational Science Center for Molecular Medicine of Air Force Medical University, major general of air force and professor, doctoral supervisor. Vice-chief expert of National Science and Technology Major Project of the Ministry of Science and Technology of China on major drug discovery; Member of the standing committee ofPLA Medical Scientific and Technology Committee and director of foundation and pharmacy; Vice-president of Shaanxi Association for Science and Technology; Member of Decision-making Advisory Committee of Shaanxi Province; Member of the Scientific Advisory Group of People's Government of Shaanxi Province; Science and technology consultant of Xi'an Municipal People's Government; Supervisor of Chinese Pharmaceutical Association; Chairman of Innovation Strategic Alliances of China Translational Medicine and Biotechnology; Editorial Committee ofJ Biol Chem,Hepatology,Science in China Series C: Life Sciences, etc. He has been awarded National Outstanding Scientific and Technological Worker, National Outstanding Backbone Teacher of Higher Learning, Excellent Teacher of Chinese PLA, Excellent Postgraduate Tutor of Chinese PLA, Outstanding Professional and Technical Talent Award of Chinese PLA, gold medal for Talents education in Military Academies, gold star in Science and Technology of the General Logistics Department, Changjiang Scholars and Innovative Research Team in University of Ministry of Education of China, Military science and technology innovation group, the General Logistics Department Excellent Teaching team, Shaanxi Sanqin Scholars Innovation team leader.He has a long history of basic and translational research in cellular and molecular medicine. He originally discovered the multi-temporal, multi-stage, and multi-node regulatory mechanism of inflammatory-cancer related molecule CD147 in cancer progression. He was the first to discover the pathogenic mechanism of major infectious diseases such as falciparum malaria and COVID-19 invading host cell receptors and their interaction with ligands, which is at the international advanced level. His research and development of new target antibody drugs and immune cell therapy products are leading in the world. He has established key technology platforms such as humanization and industrialization of antibodies, animal drug evaluation system of transgenic model, and immune cell reprogramming. He has published 255 SCI papers inNature,Cell Matab,Mol Cancer,Blood,and other international top journals and professional magazines, including 1 ESI hot paper (Top 1 ‰) and 4 highly cited papers (Top 1%); Awarded ESI Highly cited Scholar, "Top one hundred thousand Scientists in the world"; Owned 5 international patents and 35 national invention patents; Received 1 national class I new drug certificate, 1 class III medical device certificate, 2 new drug clinical trial approvals, 5 international clinical trial approvals, 4 clinical access for cell therapy products; Won the second prize of National Science and Technology Progress Award and 12 provincial and ministerial first prizes, 3 items of the top ten progress of national medicine and health / Chinese medicine and biotechnology, 1 item of the China Association for Science and Technology's 2021 "Science and Technology Innovation China" list for leading technology.